Skip to main content

Table 1 Demographics, clinical characteristics and treatment of patients recovered from COVID-19 with positive results of SARS-CoV-2

From: Positive results for patients with COVID-19 discharged form hospital in Chongqing, China

 Patients (n = 61)
Age, years54.79 (12.89)
 ≤ 293 (4.9%)
 30–397 (11.5%)
 40–4912 (19.7%)
 50–5918 (29.5%)
 60–6915 (24.6%)
 70–796 (9.8%)
Sex
 Female36 (59%)
 Male25 (41%)
Chronic medical illness24 (39.3%)
 Chronic obstructive pulmonary disease8 (13.1%)
 Hypertension5 (8.2%)
 Diabetes5 (8.2%)
 Digestive system disease2 (3.3%)
 Cerebrovascular disease1 (1.6%)
 Chronic kidney disease1 (1.6%)
 Chronic hepatitis2 (3.3%)
Symptoms after discharge from hospital
 Fever15 (24.6%)
 Sore throat8 (13.1%)
 Cough11 (18%)
 Shortness of breath3 (4.9%)
 Sputum production9 (14.8%)
 Headache5 (8.2%)
 Fatigue3 (4.9%)
 Diarrhoea3 (4.9%)
 Asymptom38 (62.3%)
Positive results
 Nasal and pharyngeal swab36 (59%)
 Stool17 (27.9%)
 Sputum8 (13.1%)
Disease severity status
 Mild38 (62.3%)
 General20 (32.8%)
 Severe3 (4.9%)
 Critical0
Laboratory findings
 Leucocyte count (×  109 per L; normal range 3.5–9.5)6.9 (4.5–8.5)
  > 9.58 (13.1%)
  < 3.511 (18%)
 Neutrophil count (× 109 per L; normal range 1.8–6.3)4.9 (3.4–5.9)
  > 6.314 (22.9%)
 Lymphocyte count (× 109 per L; normal range 1.1–3.2)1.5 (0.8–1.9)
  < 0·817 (27.9%)
 Platelets count (× 109 per L; normal range 100–300)155 (128–175)
  < 1004 (6.6%)
 Procalcitonin, ng/mL (normal range < 0.05)
  ≥ 0.05, n (%)6 (9.8%)
 C-reactive protein (mg/L; normal range 0–5)3.2 (1.7–28.6)
  ≥ 5.019 (31.1%)
 D-dimer (mg/L; normal range 0–500)164 (65–327)
  > 5007 (11.5%)
 Albumin (g/L; normal range 40–55)33.7 (28.4–37.6)
  < 4058 (95.1%)
 Alanine aminotransferase (U/L; normal range 9–50)27 (19–36)
  > 505 (8.2%)
 Aspartate aminotransferase (U/L; normal range15–40)24 (15–33)
  > 404 (6.6%)
 Blood urea nitrogen (mmol/L; normal range3.6–9.5)6.1 (4.7–7.3)
  > 9.55 (8.2%)
 Serum creatinine (μmol/L; normal range 57–111)80 (67–95)
  > 1119 (14.8%)
 Lactate dehydrogenase (U/L; normal range 120–250)172 (150–262)
  > 25014 (22.9%)
Radiologic findings
 Abnormalities on chest radiograph23 (37.7%)
  Ground-glass opacity3 (4.9%)
  Local patchy shadowing9 (14.8%)
  Bilateral patchy shadowing8 (13.1%)
  Interstitial abnormalities3 (4.9%)
 Normalities on chest radiograph38 (62.3%)
Length of stay in hospital, days18.0 (14.0–22.5)
Length of positive result for COVID-19 after hospital discharge, days10 (7–13)
 < 1447 (77%)
 14–289 (14.8%)
 > 285 (8.2%)
Treatment
 Oxygen therapy21 (34.4%)
 Non-invasive mechanical ventilation2 (3.3%)
 Antiviral treatment23 (37.7%)
 Antibiotic treatment20 (32.8%)
 Glucocorticoids2 (3.3%)
 Convalescent plasma therapy3 (4.9%)
Clinical outcomes at data cutoff
 Hospitalization22 (36.1%)
 Hospital Discharge1 (1.6%)
 Centralized isolation for medical observation38 (62.3%)
  1. Data are n (%), mean (SD) and median (IQR).OVID-19: coronavirus disease 2019, SARS-CoV-2: severe acute respiratory syndrome coronavirus 2